Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of treating peripheral t cell lymphoma using Anti-cd30 antibody drug conjugate therapy

An antibody drug, lymphoma technology, applied in the field of treatment of peripheral T-cell lymphoma, can solve problems such as no randomized research has been carried out

Pending Publication Date: 2021-11-05
SEAGEN INC
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The high rate of subsequent disease progression in patients who respond to first-line therapy has led some investigators to adopt stem cell transplantation (SCT) as a way to improve long-term outcomes; however, no randomized studies have been performed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating peripheral t cell lymphoma using Anti-cd30 antibody drug conjugate therapy
  • Method of treating peripheral t cell lymphoma using Anti-cd30 antibody drug conjugate therapy
  • Method of treating peripheral t cell lymphoma using Anti-cd30 antibody drug conjugate therapy

Examples

Experimental program
Comparison scheme
Effect test

example

[0119] Bentuximab administered sequentially or concurrently with multiagent chemotherapy was previously evaluated in a Phase 1 study (Study SGN35-011) in patients with newly diagnosed CD30-positive mature T-cell and NK-cell tumors, including sALCL Clinical safety and activity of monoclonal antibodies. This Phase 1 study was conducted to determine the safety and activity of sequential and combined first-line treatment approaches of Bentuximab with CHOP or CHP chemotherapy. The maximum tolerated dose of gentuximab administered with CHP was 1.8 mg / kg. In an interim analysis of this study (data presented at T-Cell Lymphoma Forum 2012), 20 patients in this study had been treated with 1.2 or 1.8 mg / kg vedotin of gentuximab given concomitantly with CHP for 6 cycles, then for responding patients continue treatment with gentuximab every 3 weeks for a maximum of 10 additional cycles.

[0120] Given the treatment outcomes with burtuximab in relapsed and refractory settings and its demo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure, relates, in general to methods treating peripheral T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to US Provisional Patent Application 62 / 739,631, filed October 1, 2018, which is hereby incorporated by reference in its entirety. technical field [0003] The present disclosure relates generally to the treatment of peripheral T-cell lymphoma by administering anti-CD30 antibody drug conjugate therapy in combination with a chemotherapy regimen of cyclophosphamide, doxorubicin, and prednisone method. Background technique [0004] Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas (NHLs). PTCL accounts for approximately 10% of all NHL cases in the United States and Europe, and may be as high as 24% in Asia. The most common subtypes of PTCL (including PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase (ALK)-positive / negative anaplastic large cell lymphoma ( ALCL)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/68A61P35/00A61K31/573A61K31/675A61K31/704
CPCA61K47/6849A61K31/675A61K31/704A61K31/573A61P35/00A61K47/68031A61K2300/00A61K47/6801C07K16/2878A61K47/6867A61P35/02
Inventor 托马斯·曼利尼尔·约瑟夫森
Owner SEAGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com